InvestorsHub Logo
Followers 1
Posts 52
Boards Moderated 0
Alias Born 01/28/2017

Re: vidpok45 post# 1248

Monday, 03/13/2017 12:36:21 AM

Monday, March 13, 2017 12:36:21 AM

Post# of 17421
You hit the ball out of the park with your buyout analysis Vid. Glickman and Company will absolutely consider "all the potential indications", not just Lupus Nephritis, when dealing with big pharma. Based on previous Voclosporin clinical trials, other indications should include; Organ Transplantation Anti Rejection, Uveitis and Psoriasis. Your 3-5 billion is a much more realistic buyout figure.

Hang on boys... Could be rough seas ahead
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News